I IIS Aragón Photography Contest
23 December, 2020
X-ray of the new strain: "A few mutations do not usually change the effectiveness of the vaccine"
23 December, 2020
Professor of Biochemistry Alberto Anel together with his group "Apoptosis, Immunity and Cancer" at the University of Zaragoza, collaborate with the company Phosplatin Therapeutics LLC.
Professor of Biochemistry Alberto Anel together with his group "Apoptosis, Immunity and Cancer" at the University of Zaragoza collaborate with the company Phosplatin Therapeutics LLC, a United States biotechnology company in the development of a new antitumor against bone metastasis. The company Phosplatin Therapeutics LLC has developed a new molecule, PT-112, which demonstrates a unique combination of anti-cancer properties and an attractive profile of tolerability and action on bone metastases.
The "Apoptosis, Immunity and Cancer" research group, attached to the Institute of Health Research of Aragon (IIS-Aragón), collaborates with this company to determine the mechanism by which it induces cell death in tumors.
Furthermore, it is being shown that this drug has a greater action on tumors with their more altered metabolism, which also tend to produce more metastasis, reports the University of Zaragoza in a press release. This is making it possible to identify markers of susceptibility to the drug, which could be very relevant in relation to its use in patients.
This work is being carried out primarily by doctoral student Ruth Soler, with a contract from Phosplatin Therapeutics through the OTRI of the University of Zaragoza, in collaboration with company scientists, such as Tyler Ames and José Jimeno, supervised by CEO Matthew R. Price.
The latest data on this research have been shown at the latest joint congress of the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), one of the most prestigious in the area of cancer treatment.
"The data released at the 32nd EORTC-NCI-AACR Virtual Symposium advance knowledge regarding the mechanism of action of PT-112 and offer valuable information about its potential clinical applications. As we continue our clinical study of this compound in patients with difficult cancers, such insights are important," notes Robert Fallon, co-founder and CEO of Phosplatin Therapeutics.
"We are delighted to jointly present this work under our fruitful collaboration with the laboratory of Professor Alberto Anel," highlights Fallon.
PT-112 is a new conjugate of platinum with pyrophosphate that is capable of inducing cell death in various tumors, which in turn induces activation of the immune system against the tumor. That is why its combination with immunotherapy is being studied. PT-112 is currently in phase II clinical trials in prostate tumors and multiple myeloma in the US.
The first clinical study of PT-112 was conducted in 2018 and demonstrated a good safety profile and evidence of durable responses among pre-treated patients. In addition, PT-112 has a high propensity to reach bone, which increases its interest in types of cancer that occur or metastasize to bone.
